Intranasal RNA therapy shows promise against SARS-CoV-2 with dual-targeting approach
A novel intranasal nanomedicine targeting SARS-CoV-2 shows partial viral load reduction in mice, utilizing hpDNAs and baicalein.
Asset / Drug
Drug and asset intelligence for Intranasal with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.